AlloVir (NASDAQ:ALVR) Stock Price Up 8.2% – What’s Next?

AlloVir, Inc. (NASDAQ:ALVR) rose 8.2% during trading on Friday . The company traded as high as $9.50 and last traded at $9.74. Approximately 34,835 shares were traded during mid-day trading, a decline of 2% from the average daily volume of 35,517 shares. The stock had previously closed at $9.00.

AlloVir Stock Performance

The firm has a market capitalization of $1.07 billion, a P/E ratio of -10.55 and a beta of 0.65. The firm has a 50 day simple moving average of $11.28 and a two-hundred day simple moving average of $15.67.

AlloVir (NASDAQ:ALVR) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.22) by $2.30.

Hedge Funds Weigh In On AlloVir

An institutional investor recently raised its position in AlloVir stock. Cubist Systematic Strategies LLC boosted its holdings in AlloVir, Inc. (NASDAQ:ALVR) by 152.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 49,816 shares of the company’s stock after purchasing an additional 30,072 shares during the period. Cubist Systematic Strategies LLC’s holdings in AlloVir were worth $36,000 as of its most recent SEC filing. Institutional investors and hedge funds own 66.05% of the company’s stock.

About AlloVir

AlloVir, Inc engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.